摘要
目的探讨沙美特罗替卡松联合沙丁胺醇治疗慢性阻塞性肺疾病(COPD)的临床疗效及对血清白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平的影响。方法选择2012年1月—2014年10月收治的COPD 92例,随机分为观察组和对照组,每组46例。两组均给予常规治疗,在此基础上,对照组给予沙丁胺醇治疗,而观察组给予沙美特罗替卡松联合沙丁胺醇治疗。观察两组肺功能、IL-6和TNF-α水平、临床疗效及不良反应发生情况。结果与对照组比较,观察组肺功能明显改善,IL-6和TNF-α水平显著降低(P<0.05)。观察组总有效率高于对照组(P<0.05)。两组均未发生严重不良反应。结论沙美特罗替卡松联合沙丁胺醇治疗COPD效果好,不良反应轻微。
Objective To investigate the clinical effect of Salmeterol Xinafoate and Fluticasone Propionate combined with Albuterol in treatment of chronic obstructive pulmonary disease （COPD） and its effects on levels of serum interleukin-6 （IL-6） and tumor necrosis factor-α （TNF-α）. Methods A total of 92 COPD patients admitted during January 2012 and October 2014 were randomly divided into observation group （n =46） and control group （n =46）. All the patients underwent conventional treatment, the control group was treated with Albuterol, while the observation group was treated with Salmeterol Xinafoate and Fluticasone Propionate combined with Albuterol. The pulmonary function, levels of serum IL-6 and TNF-α, curative efficacy and incidence rate of adverse reactions were observed in the two groups. Results Compared with those in the control group, pulmonary function was obviously improved, and levels of serum IL-6 and TNF-α were significantly lower in the observation group after the treatment （P 〈 0.05）. The total effective rate in the observation group were significantly higher than that in the control group （P 〈 0. 05 ）. There was no ease of severe adverse reaction in the two groups. Conclusion Salmeterol Xinafoate and Fluticasone Propionate combined with Albuterol in treatment of chronic obstructive pulmonary disease can achieve good curative efficacy with very mild adverse reactions.
出处
《解放军医药杂志》
CAS
2016年第1期93-95,共3页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
关键词
沙美特罗替卡松
沙丁胺醇
肺疾病
慢性阻塞性
肺功能
白介素-6
肿瘤坏死因子-Α
Salmeterol Xinafoate and Fluticasone Propionate
Albuterol
Pulmonary disease, chronic obstructive
Lung function
Interleukin-6
Tumor necrosis factors-or
